SCIENTURE
PharmaSCIENTURE is a pharmaceutical company focused on Cardiovascular. Key products include REZENOPY.
SCIENTURE's Key Drugs
SCIENTURE's core commercial portfolio centers on ARBLI, REZENOPY, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
SCIENTURE's Recent FDA Approvals
SCIENTURE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SCIENTURE's Therapeutic Areas
SCIENTURE's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SCIENTURE's Top Competitors
SCIENTURE's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SCIENTURE Pipeline Snapshot
Active clinical trials for SCIENTURE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ARBLI leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling